Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled study of MK-4305 in primary insomnia (Study A)
2010-018413-30Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Insomnia comparing MK-4305 with Placebo (2 arms). Primary endpoint: Maintenance of treatment effect (primary endpoint). Started Mar 2010; status: completed.
02
Drugs
suvorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on 2010-018413-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018413-30.